We protect people’s lives and health, producing the world’s best technologies which are available for everyone to everyoneAbout
At the innovative Nanolek Plant in the Kirov region medicines are produced according to international GMP* and ISO 9001 standards**
Drugs for the treatment of cancer
Avelumab — Human Immunoglobulin Gl, Monoclonal antibody
Zanubrutinib is a selective low—molecular-weight inhibitor of Bruton tyrosine kinase, an oncohematological drug
Daratumumab is a monoclonal antibody that acts on the CD38 surface protein
Lomustin is an antitumor drug of alkylating action
Filgrastim — recombinant human granulocyte colony stimulating factor
Rituximab is a monoclonal antibody
Bevacizumab is a recombinant hyperchymeric monoclonal IgG1 antibody
Drugs for the treatment of orphan diseases
Iduronate-2-sulfatase is a drug for enzyme replacement therapy for Hunter syndrome
Agalsidase beta — enzyme for the treatment of Fabry's disease
Nanolek’s own R&D centre by the same name was opened in 2021 in the science city of Pushchino with the goal of developing new medicines there from scratch.
The path of a drug from a molecule to market entry takes up to 6 years. Early development of development of a single molecule takes 1-2 years. Furthermore, on average only 10 out of 100 hypotheses of molecules make it to market.